Navigation Links
Synthetech Reports Second Quarter Fiscal 2009 Results
Date:11/10/2008

(72) (742)

Income tax benefit - - - -

Net loss $(367) $(861) $(72) $(742)

Basic and diluted loss

per share $(0.03) $(0.06) $(0.00) $(0.05)

Dr. Gregory Hahn, President and CEO, stated, "We have yet to realize our goal of a return to profitable operations. However, we continue to make progress on cost improvements and manufacturing efficiencies."

Looking forward, Dr. Hahn further stated, "Synthetech's order backlog as of September 30, 2008, was approximately $5.7 million, with most of this expected to ship during the third quarter of fiscal 2009 and the balance during the fourth quarter of fiscal 2009. In October 2008, we received an order for a new project from a major pharmaceutical company for $1.3 million, which is scheduled to ship during the second and third quarters of fiscal 2010. Additionally, a few days ago we received a $5.4 million order from a major Western European pharmaceutical company for an ongoing project that is expected to ship before the end of fiscal 2009. We have been supporting this project as it advances through development phases for over two years and the customer has agreed to advance certain funds in support of the recent order."

Management anticipates that Synthetech's revenue will continue to be volatile from period to period. Variability in Synthetech's level of revenue is based primarily on its participation in large-scale customer projects and the timing of shipments arising from these projects. Synthetech operates in a challenging business environment, characterized by the unpredictable dynamics and life cycle of pharmaceutical projects, which can lead to rapid fluctuations in the mix of projects and revenues. As the uncertainties inherent in drug development projects remain outside of Synthetech's control, it is difficult to predict the progress, timing and reve
'/>"/>

SOURCE Synthetech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer
2. Omega Protein Reports 17 Cents Per Share Third Quarter Profit
3. Mesa Labs Reports Higher Quarterly Sales and Earnings
4. Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliants Results
5. NHPCO Reports Growth in Number of Hospice Patients Served, 1.4 Million, With a Wider Range of Illnesses Seen by Providers
6. Chindex International Inc. Reports Second Quarter FY 2009 Financial Results
7. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance
8. MGT Capital Investments Reports Third Quarter 2008 Financial Results and Provides Update on Recent Developments
9. LegalView Reports Record Numbers of Drug Reactions in U.S., Partially Caused by Heparin
10. China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates
11. Labopharm Reports Results for Third Quarter Fiscal 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... School of Medicine researchers have been awarded two-year grants ... Nordisk announced this month. Of the 110 initial submissions ... Science Forum Program, only four projects were funded, three ... are Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; ... a professor of oncology, will use his $500,000 proof ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... has been effective for inoperable liver cancer. It is a year since ... a 25 ... rate in either reducing tumour size or the number of tumours. Till ... tumours, who cannot be treated by any other means. ,TheraSphere ...
... who suffer from dementia benefit from music therapy. The therapy ... The trials have found that the therapy is popular with ... at Imperial College London are planning to carry out a ... has long term benefits for dementia sufferers. If their results ...
... with low birth weight can significantly improve survival rates, ... diseases. The research involved 1,154 full-term but smaller than ... 5 1/2 pounds or less. Mothers fed them supplements ... the 20 who died had not been receiving zinc ...
... sole franchisee for US based Medicine Shoppe International, with operations ... from list of its target for operations in the country. ... to expand its franchisee operations from the present 19 outlets ... has decided to put on hold the commencing of operations ...
... a heavy breakfast and a steaming cup of tea may increase ... fried food each morning are at twice the risk of ... to reduce the incidence of cancer is to begin the day ... ,Cancer of the oesophagus - the food pipe connecting the stomach ...
... are more likely to get diagnosed with the progressive brain ... the case, although some have suggested that the disease may ... before it manifests itself elsewhere. ,Dr Robert Abbott, ... effectively identify people with early or suspected disease or people ...
Cached Medicine News:Health News:Cut down on fries 2
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... multi-year, multi-hospital retrospective database analysis,demonstrates RDS treatment ... improved neonatal,survival --, NAPA, Calif. and PARMA, ... today at the Pediatric Academic Societies' Annual ... Syndrome (RDS) have a nearly 20% better ...
... Inspire,Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced results ... epinastine nasal,spray and placebo in patients with ... improvement in total nasal symptom score,dose-related effects ... higher,dose (0.1%) achieving statistical superiority over placebo., ...
Cached Medicine Technology:Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 2Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 3Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 4Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 5Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 2Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 3Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 4